---
document_datetime: 2025-10-10 11:38:59
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/carvykti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: carvykti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9232306
conversion_datetime: 2025-12-25 06:03:41.263472
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## CARVYKTI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                |
|---------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000272240 | This was an application for a group of variations. | 18/09/2025                          |                                             | Annex II, Labelling and          | The Annex II has been updated as follows: To add the manufacturer of the active substance and batch release site. The package leaflet has been updated |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active                                                                                                                                                                                                                                                                                                                                                      | PL   | accordingly.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------------|
| B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where                                                                                                                                                                                                                                                                   |      |                |
| B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of |      |                |

<div style=\"page-break-after: always\"></div>

| biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.3 Including batch control/testing for a biological/immunological product and any of the test methods performed at that site is a biological / immunological / immunochemical method - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted                                                                                                                         |            |     |                |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| Variation type II / EMA/VR/0000281226 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted             | 18/09/2025 | N/A | Not applicable |
| Variation type II / EMA/VR/0000285085 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.e Deletion of a specification parameter which may have a significant effect on the overall quality of the active substance and/or the finished product - Accepted | 18/09/2025 | N/A | Not applicable |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000294863   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                                                                     | 04/09/2025   |     | SmPC   | To update section 4.4 of the SmPC to implement the signal recommendations on 'Ciltacabtagene autoleucel; idecabtagene vicleucel; tisagenlecleucel - Progressive multifocal leukoencephalopathy (EPITT no 20153)' adopted at the 10 July 2025 PRAC.   |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000287523      | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted                                                                                                                                                                                                                                                                  | 20/08/2025   | N/A |        |                                                                                                                                                                                                                                                      |
| Variation type II / EMA/VR/0000258113      | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted | 24/07/2025   | N/A |        |                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                       | starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted                                                                                                              |            |     |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000264446 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.4 of the SmPC in order to amend an existing warning on Secondary malignancies including of T-cell origin to limit the testing only to secondary malignancy of T-cell origin based on the data from clinical studies and literature and to give instruction on monitoring and testing of secondary malignancy of any type in treated patients with HIV. | 24/07/2025 |     | SmPC | SmPC new text: Patients should be monitored life- long for secondary malignancies. In the event a secondary malignancy occurs, the company should be contacted for reporting and to obtain instructions on patient samples to collect for testing of secondary malignancy of T-cell origin. In patients with HIV infection, contact the company for the testing of secondary malignancies, including those of non-T cell origin. For more information, please refer to the Summary of Product Characteristics. |
| Variation type IB / EMA/VR/0000280863 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 18/07/2025 | N/A |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                       | Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                                                              |            |     |             |                   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-------------------|
| Variation type IA_IN /                | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                | 11/07/2025 |     | SmPC and PL | EMA/VR/0000285927 |
| Variation type II / EMA/VR/0000264849 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted | 19/06/2025 | N/A |             |                   |
| Variation type IA / EMA/VR/0000278722 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Deletion of one manufacturing process of the active substance manufacturing processes - Accepted                                                                                                                                                                         | 11/06/2025 | N/A |             |                   |

<div style=\"page-break-after: always\"></div>

| PASS / EMA/PASS/0000264227       |                                              | 05/06/2025   |    |
|----------------------------------|----------------------------------------------|--------------|----|
| PASS / EMA/PASS/0000256848       |                                              | 08/05/2025   |    |
| Article 61(3) / EMA/N/0000244636 | - Notification acc. Article 61(3) - Accepted | 07/02/2025   | PL |